These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35729030)

  • 1. After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis.
    Oh J; Morris WJ; Spadinger I; Tyldesley S; Keyes M; Halperin R; Crook J; Lapointe V; Pickles T
    Brachytherapy; 2022; 21(5):605-616. PubMed ID: 35729030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a surgical prostate-specific antigen threshold of >0.2 ng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial.
    Morris WJ; Pickles T; Keyes M
    Brachytherapy; 2018; 17(6):837-844. PubMed ID: 30245169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
    Oh J; Tyldesley S; Pai H; McKenzie M; Halperin R; Duncan G; Morton G; Keyes M; Hamm J; Morris WJ
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1061-1070. PubMed ID: 36528488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse.
    Laing R; Uribe J; Uribe-Lewis S; Money-Kyrle J; Perna C; Chintzoglou S; Khaksar S; Langley SEM
    BJU Int; 2018 Oct; 122(4):610-617. PubMed ID: 29607601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
    Rodda S; Morris WJ; Hamm J; Duncan G
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):581-589. PubMed ID: 28581398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
    Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
    Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
    Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
    Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness.
    Orio PF; Nguyen PL; Buzurovic I; Cail DW; Chen YW
    Brachytherapy; 2016; 15(6):701-706. PubMed ID: 27317191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes analysis of low-dose-rate brachytherapy in clinically T3 high-risk prostate cancer.
    Agarwal M; Chhabra AM; Amin N; Braccioforte MH; Molitoris JK; Moran BJ
    Brachytherapy; 2018; 17(6):882-887. PubMed ID: 30143400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer.
    Chao M; Joon DL; Khoo V; Spencer S; Ho H; Guerrieri M; Foroudi F; Bolton D
    J Med Imaging Radiat Sci; 2019 Mar; 50(1):82-86. PubMed ID: 30777253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.
    Keyes M; Merrick G; Frank SJ; Grimm P; Zelefsky MJ
    Brachytherapy; 2017; 16(2):245-265. PubMed ID: 28110898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.
    Krishnan V; Delouya G; Bahary JP; Larrivée S; Taussky D
    BJU Int; 2014 Dec; 114(6):865-71. PubMed ID: 24274784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
    Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
    Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
    Baumann BC; Baumann JC; Christodouleas JP; Soffen E
    Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy.
    Pickles T; Morris WJ; Keyes M
    Brachytherapy; 2017; 16(6):1101-1105. PubMed ID: 29032014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.